Meeting
2019 ASCO Annual Meeting
Prospective head-to-head comparative phase 3 study between 18F-fluciclovine and 68Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.
Authors
Jeremie Calais
UCLA, Los Angeles, CA
Jeremie Calais , Francesco Ceci , Matthias Eiber , Tore Bach-Gansmo , Cristina Nanni , Bital Savir-Baruch , Michael Hofman , Tom Hope , Christoph Rischpler , David Elashoff , Tristan Grogan , Magnus Dahlbom , Roger Slavik , Jeannine Gartmann , Robert Evan Reiter , Matthew Rettig , Hossein Jadvar , Wolfgang P Fendler , Johannes Czernin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer–Local-Regional Disease
Clinical Trial Registration Number
NCT03515577
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5014)
DOI
10.1200/JCO.2019.37.15_suppl.5014
Abstract #
5014
Poster Bd #
126
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk of biochemical recurrence (BCR) after radical prostatectomy (RP) in the ongoing phase 3 PRIMORDIUM study.
First Author: Boris A. Hadaschik
Poster
2022 ASCO Genitourinary Cancers Symposium
Salvage radiotherapy (SRT) in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer.
First Author: Markus Grabbert
Poster
2021 ASCO Annual Meeting
Diagnostic performance of Gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging in early-relapsed prostate cancer: Phase 3, prospective, multicenter study (IAEA-PSMA study).
First Author: Juliano J Cerci